Menu Search
Equities

Sansure Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
688289:SHH

Sansure Biotech Inc

Actions
Health CareMedical Equipment and Services
  • Price (CNY)19.31
  • Today's Change-0.23 / -1.18%
  • Shares traded3.73m
  • 1 Year change-13.68%
  • Beta0.9202
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Sansure Biotech Inc had net income fall -24.23% from 363.72m to 275.60m despite a 44.78% increase in revenues from 1.01bn to 1.46bn.
Gross margin73.70%
Net profit margin13.49%
Operating margin15.96%
Return on assets2.50%
Return on equity3.78%
Return on investment2.81%
More ▼

Cash flow in CNYView more

In 2024, Sansure Biotech Inc increased its cash reserves by 7.31%, or 305.01m. The company earned 274.45m from its operations for a Cash Flow Margin of 18.82%. In addition the company generated 132.49m cash from financing while 101.92m was spent on investing.
Cash flow per share--
Price/Cash flow per share--
Book value per share12.31
Tangible book value per share9.86
More ▼

Balance sheet in CNYView more

Sansure Biotech Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.41% of the market capitalization can be attributed to its 4.57bn and debt could be paid in full if management chose.
Current ratio4.88
Quick ratio4.49
Total debt/total equity0.2097
Total debt/total capital0.1716
More ▼

Growth rates in CNY

Year on year, growth in dividends per share increased 13.59% while earnings per share excluding extraordinary items fell by -24.19%. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)2.10%
Div growth rate (5 year)--
Payout ratio (TTM)166.40%
EPS growth(5 years)44.55
EPS (TTM) vs
TTM 1 year ago		-1.07
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.